This site is currently not optimized for mobile devices. For the best user experience, please access the site via a device with a wider screen such as a desktop or laptop.

For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser.

Once enabled, click here to view the site.

signup link button why should I sign up?
Login as Volunteer Login as Study team member
OR

Studies you may be eligible for. 2

Based on the information you provided, we found the following studies.

  • A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab. Study goals: find highest safe dose of nivolumab without causing severe side effects; learn side effects nivolumab causes;learn how your body handles nivolumab;learn the effects of nivolumab on cells and proteins in blood and tumor tissue;see if nivolumab is a beneficial treatment for your tumor. This study is researching all of the following topics: Cancerous bone tumor, Osteosarcoma Hodgkin's lymphoma Melanoma NB, Neuroblastoma Non-Hodgkin's lymphoma Rhabdomyosarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • All ages welcome
  • Phase I/II Trial of experimental drug ganetespib in combination with the mTOR inhibitor sirolimus for patients with unresectable or metastatic malignant peripheral nerve sheath tumors (MPNST) Study purpose:find highest safe dose, side effects and any benefits of ganetespib when given with sirolimus; test whether 3D-MRI is better at seeing MPNST than traditional scans This study is researching all of the following topics: Cancerous bone tumor, Osteosarcoma Sarcoma This study is looking for: male female both men and women Volunteers with specific conditions
    • More than 18 years old